These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases. Gonzalez LM, Brindeiro RM, Aguiar RS, Pereira HS, Abreu CM, Soares MA, Tanuri A. Antimicrob Agents Chemother; 2004 Sep; 48(9):3552-5. PubMed ID: 15328124 [Abstract] [Full Text] [Related]
25. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study. Dandache S, Coburn CA, Oliveira M, Allison TJ, Holloway MK, Wu JJ, Stranix BR, Panchal C, Wainberg MA, Vacca JP. J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279 [Abstract] [Full Text] [Related]
26. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways. Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA. J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190 [Abstract] [Full Text] [Related]
27. HIV-1 protease-substrate coevolution in nelfinavir resistance. Kolli M, Ozen A, Kurt-Yilmaz N, Schiffer CA. J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428 [Abstract] [Full Text] [Related]
28. Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism. Calazans A, Brindeiro R, Brindeiro P, Verli H, Arruda MB, Gonzalez LM, Guimaraes JA, Diaz RS, Antunes OA, Tanuri A. J Infect Dis; 2005 Jun 01; 191(11):1961-70. PubMed ID: 15871131 [Abstract] [Full Text] [Related]
30. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure. Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW. AIDS Res Hum Retroviruses; 2006 Dec 01; 22(12):1300-5. PubMed ID: 17209774 [Abstract] [Full Text] [Related]
31. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations. Tzoupis H, Leonis G, Avramopoulos A, Mavromoustakos T, Papadopoulos MG. J Phys Chem B; 2014 Aug 14; 118(32):9538-52. PubMed ID: 25036111 [Abstract] [Full Text] [Related]
33. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Jenwitheesuk E, Samudrala R. Antivir Ther; 2005 Aug 14; 10(1):157-66. PubMed ID: 15751773 [Abstract] [Full Text] [Related]
39. Effectiveness of commercial inhibitors against subtype F HIV-1 protease. Krauchenco S, Martins NH, Sanches M, Polikarpov I. J Enzyme Inhib Med Chem; 2009 Jun 24; 24(3):638-45. PubMed ID: 18825538 [Abstract] [Full Text] [Related]
40. Protease inhibition in African subtypes of HIV-1. Velázquez-Campoy A, Vega S, Fleming E, Bacha U, Sayed Y, Dirr HW, Freire E. AIDS Rev; 2003 Jun 24; 5(3):165-71. PubMed ID: 14598565 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]